CJC-1295 in Australia: a GHRH-analogue research guide

CJC-1295 in Australia. CJC-1295 (no DAC) — also catalogued as Mod GRF (1-29) — is a 30-residue stabilised analogue of growth-hormone-releasing hormone (GHRH) referenced across growth-hormone-secretagogue research literature. This guide is a research-reference summary for Australian researchers, including the difference between the DAC and no-DAC forms and how the compound is paired with a GHRP in research. It makes no muscle, performance, or human-use claim.

What CJC-1295 (no DAC) is

CJC-1295 (no DAC) is a 30-residue synthetic analogue of the native hGRF(1-29) sequence — Mod GRF (1-29). It carries four stabilising substitutions on the GHRH(1-29) backbone (including D-Ala at position 2) plus a C-terminal amide, which slow enzymatic degradation while retaining GHRH-receptor-binding activity in research models. The value of that backbone chemistry was characterised by Soule and colleagues (The Journal of Clinical Endocrinology & Metabolism, 1994), who showed that incorporating D-Ala2 into GHRH(1-29) increases half-life and lowers metabolic clearance by blocking dipeptidyl-peptidase cleavage.

DAC vs no DAC — the distinction that matters

The “no DAC” label distinguishes this form from the DAC (drug-affinity-complex) variant. Jetté and colleagues (Endocrinology, 2005) identified CJC-1295 as an albumin-bioconjugated hGRF(1-29) analogue whose DAC group extends plasma persistence over days in research models, and Teichman and colleagues (The Journal of Clinical Endocrinology & Metabolism, 2006) reported the multi-day half-life of that DAC molecule. The no-DAC form referenced here carries the stabilising backbone substitutions but not the albumin-binding DAC group — so it is the shorter-acting, canonical reference version in GHRH research, and the form most frequently paired with a GHRP.

The GHRH + GHRP pairing

In the research literature CJC-1295 (no DAC) is most frequently studied alongside a GHRP — typically Ipamorelin, a selective ghrelin / GHS-R1a-receptor agonist. The canonical research pairing combines one GHRH analogue and one GHRP because the two receptor classes act on distinct, convergent points of the same somatotrophic-axis research model. For the co-lyophilised pairing in a single vial, see the CJC-1295 + Ipamorelin research blend and the research-stack guide.

Identity, purity and the COA moat

Every batch of CJC-1295 (no DAC) supplied by Elite AU Peptides is independently HPLC-tested by Janoshik before it is listed. The measured purity is published on the CJC-1295 (no DAC) product page and in the lab-reports library — real batch number, measured percentage, independently verifiable at janoshik.com. CJC-1295 (no DAC) is stocked in 5mg and 10mg lyophilised vials; nothing is listed without a certificate on file.

Reconstitution and handling for research use

CJC-1295 (no DAC) ships as a lyophilised powder. Reconstitute with bacteriostatic water for laboratory handling — for example, a 5mg vial in 2.5mL yields a 2mg/mL working stock. Store the lyophilised powder at −20°C protected from light; once reconstituted, refrigerate at 2–8°C and use within the documented research window, or aliquot and freeze to avoid repeated freeze-thaw cycles.

Compliance and research-use framing

CJC-1295 (no DAC) is not TGA-approved and is not a therapeutic good. Elite AU Peptides supplies it strictly for in-vitro and laboratory research use only — not for human or animal consumption. We make no medical, performance, muscle, or human-use claim; the material above summarises the published GHRH-analogue literature for reference only. Researchers should consult primary peer-reviewed sources for receptor-binding affinities and protocol-specific reference values.